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INTRODUCTION 
Turner syndrome is a chromosomal condition where a 
missing X chromosome gives a karyotype of 45, X. It 
is a condition affecting females causing developmental 
disability and multi-systemic medical complications. It 
can be suspected antenatally by ultrasonography and 
diagnosed by genetic testing from amniocentesis or 
chorionic villous sampling. At birth, newborns may 
present with lymphoedema of the hands and feet as a 
result of poor lymphatic development. It is however 
most evident at the age of 6 years owing to short 
stature [3].
 
 Early diagnosis is important as it entails 
thorough follow-ups in detecting multi-systemic 
complications. For example, as a result of 
hypogonadism, affected females are complicated by 
primary amenorrhea, infertility and young-onset 
osteoporosis. Other systemic involvements include 
coarctation of aorta, aortic valve disease, horseshoe 
kidney and other metabolic diseases. We report a case 
of Turner Syndrome diagnosed at a late age of 16 
years. 
 
CASE PRESENTATION 
A 22-year-old lady who is currently under Putrajaya 
Hospital’s endocrinology clinic follow-up was first 
referred for short stature at the age of 16 years. She 
was noticeably shorter than her peers since primary 
school but this was not picked up by both her parents 
and the general practitioners whom she visited on 
numerous occasions for minor ailments. She only 
sought medical attention for short stature and primary 
amenorrhoea at 16 years of age when the parents 
became increasingly worried. She was not known to 
have any medical or chronic childhood illnesses nor 
was she taking prescribed medications. Her paternal 
height was 176cm and maternal height was 150cm, 
giving a mid-parental height of 156.5cm ± 10cm. She 
had 3 younger siblings aged 20, 18 and 17 years who 
were all taller than her. 
 On her first clinic review, she measured 
136cm in height and 37.1kg in weight which were 
markedly below the 5th centile. Her body mass index 
was 20 kg/m
2
 with a blood pressure of 102/61 mmHg 
and pulse rate of 88 beats per minute. 
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Turner syndrome is one of the most common sex chromosome abnormalities with an 
estimated true prevalence of 1 in 2,000 in newborns. This case report is of a girl who 
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explore the diagnostics of Turner syndrome, hormone treatments available and the 
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     (b) 
Figure 1 (a) & (b) Short stature with broad shoulders, cubitus 
valgus and abnormal upper-to-lower body segment ratio are 
features of Turner syndrome. Short 5th metacarpals are also seen. 
 
 
Clinically, breasts were at Tanner stage 3 and pubic 
hair Tanner stage 2. She was also found to have 
bilateral cubitus valgus (Figure 1). No other syndromic 
features, webbed neck, spinal deformity, lymphedema 
of the limbs or goitre were evident and systemic 
examination was unremarkable. 
 She had delayed bone age of an 11-year-old 
and blood investigations revealed low estradiol (<20 
pg/ml), low progesterone (0.2ng/ml) with elevated 
Follicle Stimulating Hormone (110.53 mIU/ml) and 
Luteinizing Hormone (28.52 mIU/ml), suggesting 
primary hypogonadism. Thyroid function test, serum 
calcium, serum phosphate and blood counts were 
within normal levels. Her serum calcidiol was at an 
adequate level of 32 ng/dL. Chromosomal analysis 
from 7 analysable metaphase identified an 
isochromosome on the long arm of the X chromosome 
(q10;q10), confirming the diagnosis of Turner 
syndrome. Echocardiogram was normal with no 
coarctation of the aorta (CoA) or bicuspid aortic valve 
(BAV). Ultrasound of the kidney-ureter-bladder 
system showed a normal right kidney and multiple 
cysts occupying the left kidney. The largest cyst was at 
the renal pelvis which measured 4.4 x 4.7cm. 
 As she measured a mere 136cm at 16 years of 
age, a trial of 0.054 mg/kg/day growth hormone 
therapy (13.5mg a week) was initiated in October 
2010. The growth hormone doses were divided to 
1.9mg on weekdays and 2.0mg on weekends. Three 
months later, her height increased by 0.5cm and 
subsequently to 138.4cm at 12 months, giving a 
growth of 2.4cm in a year. Growth hormone was 
stopped after a year of therapy due to poor response.  
She attained spontaneous menarche at age 17 years 
which was of regular 28-day cycle with 3 bleeding 
days. However, as her menses stopped 4 cycles later, 
oral Premarin (conjugated oestrogen) 0.3125mg OD 
was started. This was increased to 0.625mg OD when 
she was 18 years following failure to menstruate on the 
initial dose. Menses eventually became regular at 19 
years upon adding medroxyprogesterone acetate with 6 
bleeding days per monthly cycle. She also attained 
Tanner breast stage 4 and grew axillary hair requiring 
weekly shaving. 
 Regular monitoring of blood sugar and 
cholesterol diagnosed her with type 2 diabetes mellitus 
in June 2011 (modified glucose tolerance test 5.6/11.7 
mmol/L, HbA1c 6.1%) and she was commenced on 
oral Metformin 500mg BD. She was otherwise 
asymptomatic of diabetes mellitus. Fasting lipid profile 
revealed a total cholesterol of 5.5 mmol/L, high-
density lipoprotein (HDL) of 1.1mmol/L, low-density 
Turner Syndrome and Its Complications 
 
 
Vol 3(2) (2018) 51-55 | jchs-medicine.uitm.edu.my | eISSN 0127-984X 
 
53 
lipoprotein (LDL) of 2.72 mmol/L and 
hypertriglyceridemia (triglycerides 3.7mmol/L).  
 A bone mineral density (BMD) scan in March 
2014 showed osteoporotic hips (femoral neck Z-score -
3.6) and an osteoporotic spine (lumbar Z-score -3.1) 
for which calcium supplements were added to her 
hormonal treatment. A repeat BMD scan after 1 year 5 
months yielded a lumbar Z-score of -3.1 and hip Z-
score of -3.1. 
 When she was seen at the age of 22 years, she 
was still of short stature with cubitus valgus (Figure 1). 
She was consequently switched to combined hormonal 
therapy consisting of estradiol valerate 2mg and 
Norgestrel 500mcg OD. A repeat BMD scan is 
planned in 2 years. 
 
DISCUSSION 
Turner Syndrome is caused by a partial or complete 
absence of the X chromosome in a female, with 
manifestations including short stature, ovarian failure 
and cardiovascular disease. Several karyotypes exist, 
the most common being 45 X, followed by 
isochromosome Xq as seen in this reported case and 
mosaicisms [1]. Studies show that most patients are 
diagnosed at a median age of 6.6 years or 5 years after 
falling below the 5
th
 height centile, with the 
isochromosomes and mosaic groups being diagnosed 
even later, as they present with a less typical 
phenotype as compared to the 45 X group [1-3]. 
However, due to diagnostic vigilance both prenatally 
and during childhood, the age at diagnosis is 
decreasing where more 45 X types are diagnosed 
before 1 year of age [3]. 
 Many conditions are associated with the 
syndrome including hypertension, diabetes mellitus, 
hyperlipidemia, infertility, renal malformations e.g. 
horseshoe kidneys, autoimmune thyroiditis, coeliac 
disease, lymphedema, osteoporosis and cardiac 
anomalies especially bicuspid aortic valves and aortic 
coarctation [4, 5]. These cardiac anomalies, coupled 
with syndrome-associated risk factors like 
hypertension, diabetes, hyperlipidemia and oestrogen 
deficiency, put patients at an even higher risk of 
developing and dying from coronary heart disease than 
the general population, with a standardized mortality  
ratio (SMR) of 3.47 from Coronary artery disease 
(CAD) alone [1, 5]. Other common causes of death 
include congenital abnormalities (SMR 24.09), 
endocrinal/metabolic diseases (SMR 5.68), infections 
(SMR 4.68) and diseases of the nervous system, ears 
and eyes (SMR 4.38) [1]. 
 Realizing the many associated conditions and 
complications of the syndrome, it is imperative that 
early recognition, diagnosis and treatment initiation by 
medical personnel are undertaken. 
 Diagnosis can be done as early as the prenatal 
period where non-specific ultrasonography findings 
such as nuchal translucency, cystic hygromas, cardiac 
defects, renal anomalies and growth retardation 
followed by a karyotyping study can predict Turner 
Syndrome [2, 4]. However, the ability to detect foetal 
abnormalities on ultrasonography is operator-
dependent and karyotyping studies may yield false 
positivity as high as 30% [4]. Therefore, a repeat 
confirmatory karyotyping study is needed after birth. 
 Postnatal indications for karyotyping include 
lymphoedema which commonly presents during 
infancy up to 2 years of age, growth retardation, 
pubertal delay, left-sided cardiac anomalies, 
phenotypical features and chronic otitis media [2, 4]. A 
30-cell karyotype is the recommended test by the 
American College of Medical Genetics for its ability to 
detect at least 10% of mosaicism [6]. Adequate 
number of cells is important to detect mosaicism 
which can be missed especially in women with little 
features to suggest Turner Syndrome. Should the 
patient also present with virilism, screening for Y-
chromosome material is strongly advocated as there is 
a 5-30% risk of developing gonadoblastoma requiring 
gonadectomy [2, 4]. 
 Management is multidisciplinary where 
primarily paediatricians, paediatric endocrinologists, 
adult endocrinologists and cardiologists are involved. 
In this case report however, only hormonal therapy in 
improving growth and pubertal induction is discussed. 
 Short stature is defined as a height of 2 
standard deviations below the mean or a height below 
the lower limit of mid-parental height. As short stature 
is the predominant presentation, frontline clinicians 
should be cognizant of Turner syndrome when faced 
with a slow- growing child. Early referral to experts 
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for further work-up and treatment have been useful in 
preventing disease complications. 
 Management includes increasing height with 
growth hormone at an FDA-approved dose of 
0.375mg/kg/week daily whilst monitoring height 
increment and IGF-1 levels [4]. A Canadian study has 
proven that with 0.3mg/kg/week of growth hormone, 
patients are able to grow 7.2cm taller than the control 
group after 5.7 years of therapy [7]. Treatment is 
commenced the moment growth failure is identified 
and discontinued when targeted height is achieved [4]. 
Note that final height is influenced by height at therapy 
initiation, parental height, duration of therapy and 
growth hormone dose [2]. 
 Unfortunately, this patient had only achieved 
suboptimal height due to late diagnosis hence late 
initiation of therapy. According to the International 
Turner Syndrome Consensus Group 2017 guidelines, 
growth hormone therapy should be commenced around 
4-6 years of age when there is evidence of growth 
failure [10].  
 Benefits of growth hormone therapy, apart 
from increased final height, include improved body 
proportions, lower diastolic blood pressure, improved 
lipid profiles and improved insulin resistance. The 
therapy, however, does not have an effect on bone 
mineral density [2]. Despite the known hyperglycemic 
effects of growth hormone, a 7-year study has shown 
that therapy with the hormone does not worsen glucose 
tolerance hence monitoring glucose tests or HbA1c on 
an annual basis is sufficient [8]. 
 For girls above 9 years old with severe short 
stature, the anabolic steroid, oxandrolone may be 
added at a dose of 0.05mg/kg where an increase by 
4cm in height is seen in comparison to patients on 
growth hormone therapy alone. However, side effects 
like altered liver enzymes, virilization, hypertension 
and underdeveloped breasts are cautioned [2]. 
Increasing final height by delaying pubertal induction 
is no longer recommended in view of its negative 
outcome on bone mineral density [2, 4]. 
 Pubertal induction is done to achieve 
feminization (breast & uterine development) and to 
prevent osteoporosis by administering oestrogen to 
non-pubescent Turner syndrome patients. However, as 
up to 30% of patients may achieve spontaneous 
puberty, delayed puberty should be ruled out by 
measuring serum LH & FSH prior to initiating therapy 
[4]. 
 The recommended age for oestrogen 
replacement initiation is 11-12 years [10].
 
While there 
is no fixed protocol on oestrogen regimes, the general 
consensus is to tailor the dose and forms to suit the 
normal pubertal development of the patient’s age. The 
American CPG has set an adult oestrogen dose of 
2mg/day for oral forms, 0.1mg/day for transdermal 
forms and 2.5mg/month for injectable forms. The 
recommendation is to start at 10% of the adult dose 
and to titrate up over 2-4 years [4]. Progestin is only 
added 2 years following oestrogen therapy initiation or 
upon breakthrough bleeding considering its ability to 
interfere with optimal breast & uterine development 
[2, 4]. Oral contraceptive pills are therefore not 
recommended for replacement due to its higher doses 
of oestrogen and presence of progesterone [4]. 
 Theoretically, with pubertal induction, bone 
matures sooner hence the final height may be reduced. 
However, a recent Japanese study has shown that by 
starting at 1% of adult dose (ultra-low dose) of 
oestrogen and gradually titrating it up over the years 
does not interfere with growth but at the expense of an 
ideal bone mineral density [9]. This is supported by 
another study where initiating low-dose oestrogen 
therapy as early as 5 years of age as opposed to the 
recommended 12 years, may further increase final 
height by 2.1cm on top of improving cognitive and 
hepatic functions [2, 4]. Apart from using oestrogen at 
low doses, transdermal or depot forms are also 
alternatives should growth hormone therapy 
interferences, suboptimal final height and 
thrombophilia be of concern [2, 9]. 
 The pitfall in this case was failing to identify a 
treatable cause of short stature in a timely fashion 
where family members, peers, educators and 
physicians overlooked the need to refer her for 
evaluation. This calls for increased public awareness 
that short stature should not be passed as a norm, 
perhaps through advertisement via the mass media. 
Attending doctors should be observant and not limit 
their clinical evaluations to the patient’s unrelated 
presenting complaint at clinic visits. One way to 
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achieve this is through regular continuous medical 
education lectures on the relevant subjects. 
 
CONCLUSION 
This case report exemplifies the negative repercussions 
of diagnosing and treating Turner syndrome late. Due 
to delayed initiation, growth therapy failed to yield 
optimal final height. Hormone therapy also failed to 
prevent osteoporosis thus management was focused on 
slowing down osteoporotic progress and preventing 
fractures. 
 In terms of monitoring, annual assessment of 
lipids, thyroid function, glucose studies, cardiac 
function and bone mineral density is suggested. An 
ultrasound of the urorenal system should also be 
conducted at presentation to look for malformations. 
 Both healthcare providers and the public 
should be made aware of the importance of 
investigating short stature as some important causes 
are treatable. The need for mass newborn screening in 
Malaysia may not be practical at the current time 
unless a national epidemiological study on short 
stature and Turner syndrome recommends otherwise. 
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